INSYS Therapeutics provided an update on its product pipeline, which includes cannabidiol oral solution as well as epinephrine and naloxone nasal sprays. “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “Through this intense focus on our reprioritized pipeline over the last year, which has been anchored by a patient-centric mission and commitment, we are radically transforming this company. As we look forward, we have the potential to submit six new drug applications over the next three years, two of which are scheduled for 2019.” INSYS previously announced plans to begin a strategic alternative review of its opioid-related assets and the process remains on schedule. Nine companies have signed confidential disclosure agreements and have begun a review of confidential information materials. The company will provide an update on the process during the fourth quarter 2018 earnings call in early 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.